7th Jul 2020 13:47
7 July 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 3 July 2020 it purchased 99,999 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.90p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 65,463,157 Ordinary Shares, equivalent to 22.18% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 65,463,157 Ordinary Shares of the Company representing 22.18% of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the EU Market Abuse regulation.
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Martin Diggle | ||||
Reason for the notification | ||||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial Notification | ||||
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: | Proteome Sciences Plc | ||||
b) | LEI: | 213800Q62ICXANKU2986 | ||||
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
| ||||
e) | Date of the transaction: | 3 July 2020 | ||||
f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||
For further information:
Proteome Sciences plc |
| |
Dr Ian Pike, Interim Chief Executive Officer/ Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
|
Richard Dennis, Chief Commercial Officer |
| |
| ||
Allenby Capital Limited (Nominated Adviser & Broker) |
| |
John Depasquale / Jeremy Porter
| Tel: +44 (0) 20 3328 5656 | |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Related Shares:
Proteome